News

The approval was based on positive data from multicenter, double-blind trial conducted in 127 pediatric patients between one to 11 years of age with GERD. Eisai president and

On 15 July 2011, the US Food and Drug Administration (FDA) had approved the product. As part of the agreement, Aptalis will produce and supply the product to

Diphenhydramine Hydrochloride Injection, USP, is an injectable antihistamine effective in adults and pediatric patients excluding infants and neonates. BD executive vice president and chief operating officer William Kozy

Ospemifene is developed as as vulvar and vaginal atrophy (VVA) therapy in post-menopausal women. Shionogi CEO Takashi Takenoshita said the US Food and Drug Administration has approved ospemifene

Life Technologies’ lentiviral vector technology will be leveraged in the development of next generation upcyte cells for biopharma and academic research markets. Medicyte CEO Dr. Joris Braspenning said,

The application includes safety and efficacy data of the investigational sublingual dissolvable tablet from Phase III trials including a long-term, multi-season trial. Merck Research Laboratories senior vice president,

The company has also signed the first European distribution agreements for MDS with Mokascience in France, Bucher Biotec in Switzerland and KRD Molecular Technologies in the Czech Republic,

Ekahau Wi-Fi-based temperature sensors and Ekahau Vision software will help the Hutchinson Center to monitor and report the temperatures of several hundred refrigeration units housing specimens used in

The first subject of the study is administered with defibrotide by the medical team from National University Corporation Hamamatsu University School of Medicine (HSUM), Fukushima Medical University. The